This Thanksgiving we are expressing our sincere gratitude to patients, their families, and the researchers and clinical study sites for their continued dedication towards advancing novel treatments for broad populations of cancer patients. #DrugDiscovery #CancerResearch
Immuneering Corporation
生物技术
Cambridge，MA 2,695 位关注者
Better Medicines Through Signaling Dynamics
关于我们
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage. For more information, please visit www.immuneering.com.
- 网站
-
https://www.immuneering.com
Immuneering Corporation的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 总部
- Cambridge，MA
- 类型
- 私人持股
- 创立
- 2008
- 领域
- Computational Biology、Genomics、Drug Developement、Neurodegenerative Disease和Oncology
地点
Immuneering Corporation员工
动态
-
Our Co-founder and CEO, Ben Zeskind will participate in a fireside chat at the Piper Sandler 36th Annual Health Conference on Thursday, December 5 at 1pm ET to discuss our business strategy and universal-RAS/RAF medicines for broad populations of cancer patients. Our leadership team will also host 1:1 meetings for those interested in learning more. For more details, see our press release: https://buff.ly/49cUbHW #UniversalRAS #UniversalRAF #MAPKPathway #SolidTumors #DrugDiscovery #CancerResearch #TargetedOncology #MetastaticCancer #AdvancedCancer
-
-
In honor of National Family Caregivers Month, we celebrate the partners, family members and friends who are caring for a loved one with cancer. These everyday heroes play an important role in managing the day-to-day care of a person with cancer including meal prep, cleaning and transportation. Check out the cancer caregiver resource guide from the American Cancer Society for more information and additional resources: https://buff.ly/3xlzqL3 #CancerResearch #SolidTumors #DrugDiscovery #MetastaticCancer #AdvancedCancer
-
Let’s keep the conversation going during Pancreatic Cancer Awareness Month! Join Pancreatic Cancer Action Network today at 11am PT/2pm ET, for a free webinar bringing PanCAN community members together for a conversation about how early detection can change the course of pancreatic cancer. Learn more here: https://buff.ly/48OFPwY #PancreaticCancerAwareness #PancreaticCancerResearch #SolidTumors #DrugDiscovery #CancerResearch #MetastaticCancer #AdvancedCancer
How Early Detection Can Change the Course for Pancreatic Cancer - Thursday, 11/21
pancan.org
-
IMRX’s VP of Clinical Pharmacology, Jan de Jong, presented interim Phase 1 pharmacokinetic & pharmacodynamic data on IMM-1-104, a novel oral Deep Cyclic Inhibitor of the MAPK pathway, at the 2024 ACoP Conference. These PK/PD modeling data, combined with Phase 1 safety and activity data, suggest that 240 mg and 320 mg are viable doses to promote Deep Cyclic Inhibition of the MAPK pathway. Learn more about our pipeline here: https://buff.ly/3hL4Z5r #RASMutations #UniversalRAS #MAPKPathway #SolidTumors #DrugDiscovery #CancerResearch #TargetedOncology #MetastaticCancer #AdvancedCancer
-
-
In honor of #LungCancerAwarenessMonth, we join with communities across the country to raise awareness of the importance of new research and advanced therapies for the treatment of #lungcancer – especially for those living with RAS mutant #lungcancer. The American Lung Association encourages you to assess your risk through screening to detect lung cancer early, when it is more likely to be curable. Learn more here: https://buff.ly/44fHIQ0 #LungCancerAwareness #RAS mutations #SolidTumors #DrugDiscovery #CancerResearch #MetastaticCancer #AdvancedCancer
-
-
Today we announced our third quarter 2024 financial results and recent corporate highlights. See our press release for details: https://buff.ly/3YMotfF #RASMutations #UniversalRAS #MAPKPathway #SolidTumors #DrugDiscovery #CancerResearch #TargetedOncology #MetastaticCancer #AdvancedCancer
-
-
This #VeteransDay we are proud to recognize and thank the brave men and women who protect our freedom, including the incredible members of our team who have served in the U.S. military. #ThankYouVeterans
-
-
Happy #NationalSTEMDay! Today, we celebrate the power of science, technology, engineering, and math to drive innovation. Immuneering is dedicated to developing medicines with broad activity for large populations of cancer patients. #FutureOfScience #InnovationForGood
-
-
This #PancreaticCancerAwarenessMonth, we stand in solidarity with the pancreatic cancer community worldwide. We are proud to advance important research to support this underserved group of patients. We celebrate the work of organizations like the American Association for Cancer Research that are dedicated to supporting pancreatic cancer research. Learn more about their programs supporting pancreatic cancer research here: https://buff.ly/40y1TKf #PancreaticCancerAwareness #RAS mutations #PancreaticCancerResearch #SolidTumors #DrugDiscovery #CancerResearch #MetastaticCancer #AdvancedCancer
-